Lilly’s Retatrutide Black Market Lawsuits

Eli Lilly has sued six companies and flagged 14,000+ listings globally selling black-market retatrutide — a supply chain integrity story worth tracking.

Eli Lilly has filed six lawsuits against US companies it accuses of illegally selling black-market versions of retatrutide, its still-experimental obesity drug — escalating a fight against an illicit supply chain the company says now spans more than 14,000 websites, advertisements, and product listings across over 100 countries.

Who’s Being Targeted

The lawsuits, filed in California and Texas courts, name Aesthetic Envy, Astra Peptides, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide — a mix of compounding pharmacies, a medical spa, and online peptide sellers. Several defendants market their products as “research use only” while, according to Lilly, actually selling them for direct human use. Lilly says the products are supplied by unregulated overseas manufacturers operating in facilities that haven’t been inspected or licensed by the FDA.

The Supply Chain Angle

This isn’t just an IP enforcement story — it’s a supply chain integrity problem. Lilly has referred more than 200 individuals and entities to the FDA, Department of Justice, state attorneys general, and law enforcement, and is now calling on social media platforms, e-commerce marketplaces, payment processors, and shipping and logistics carriers to help cut off distribution channels for the illicit product. The UK’s MHRA separately seized 2,000 pen injectors and tens of thousands of empty pens from a single site last October.

What This Means for Procurement and Logistics Teams

Shipping and logistics carriers are now explicitly named as enforcement partners. If your organization handles fulfillment or last-mile delivery in the wellness, compounding, or peptide space, expect increased scrutiny and potential carrier-level screening for retatrutide-related shipments going forward.

Compounding pharmacy sourcing deserves fresh due diligence. With a licensed compounding pharmacy among the defendants, buyers working with compounders on any GLP-1-adjacent product should confirm sourcing transparency now, not after a similar enforcement action affects a partner.

This is a preview of enforcement patterns for future blockbuster launches. As GLP-1 demand continues outpacing approved supply, expect similar black-market dynamics — and similar manufacturer enforcement campaigns — around future high-demand therapies still in trial.

FAQ

Why is retatrutide being sold illegally if it’s not yet approved?

Some sellers exploit a “research use only” labeling loophole to market the compound to consumers for actual human use, despite retatrutide remaining unapproved by any global regulator and still in Phase 3 trials.

How big is the illicit retatrutide market?

Lilly says it has identified over 14,000 websites, advertisements, social media posts, and product listings offering retatrutide across more than 100 countries.

What is Lilly asking logistics and payment companies to do?

Lilly is calling on social media platforms, e-commerce marketplaces, payment processors, and shipping and logistics carriers to help identify and cut off distribution channels supporting illegal retatrutide sales.

Sources

• CNBC, Lilly Sues Six Companies Over Alleged Illegal Sales of Retatrutide
• FiercePharma, Lilly Takes 6 Companies to Court for Selling Retatrutide Knockoffs
• BioPharma Dive, Lilly Files Six Lawsuits in Bid to Shut Down ‘Black Market’ for Retatrutide
• pharmaphorum, Lilly Sues Over ‘Illegal Sales’ of Obesity Drug Retatrutide